- Home
- URGN vs EBTC Comparison
URGN vs EBTC Comparison
Compare URGN & EBTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EBTC
- Stock Information
- Founded
- URGN 2004
- EBTC 1989
- Country
- URGN United States
- EBTC United States
- Employees
- URGN N/A
- EBTC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EBTC Major Banks
- Sector
- URGN Health Care
- EBTC Finance
- Exchange
- URGN Nasdaq
- EBTC Nasdaq
- Market Cap
- URGN 465.9M
- EBTC 446.9M
- IPO Year
- URGN 2017
- EBTC 2005
- Fundamental
- Price
- URGN $9.67
- EBTC $35.03
- Analyst Decision
- URGN Strong Buy
- EBTC
- Analyst Count
- URGN 7
- EBTC 0
- Target Price
- URGN $37.21
- EBTC N/A
- AVG Volume (30 Days)
- URGN 499.1K
- EBTC 38.4K
- Earning Date
- URGN 05-12-2025
- EBTC 04-17-2025
- Dividend Yield
- URGN N/A
- EBTC 2.87%
- EPS Growth
- URGN N/A
- EBTC 11.95
- EPS
- URGN N/A
- EBTC 3.27
- Revenue
- URGN $90,398,000.00
- EBTC $172,242,000.00
- Revenue This Year
- URGN $38.65
- EBTC N/A
- Revenue Next Year
- URGN $118.69
- EBTC N/A
- P/E Ratio
- URGN N/A
- EBTC $11.23
- Revenue Growth
- URGN 9.29
- EBTC 7.98
- 52 Week Low
- URGN $8.94
- EBTC $22.60
- 52 Week High
- URGN $20.70
- EBTC $44.41
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- EBTC 38.16
- Support Level
- URGN $8.94
- EBTC $33.15
- Resistance Level
- URGN $10.83
- EBTC $35.14
- Average True Range (ATR)
- URGN 0.79
- EBTC 1.50
- MACD
- URGN -0.07
- EBTC -0.07
- Stochastic Oscillator
- URGN 29.67
- EBTC 34.55
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.